Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06598943 · ClinicalTrials.gov registry record · Phase 2
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
A Phase 2 study of Ulcerative Colitis and Ulcerative Colitis Chronic, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 140
- Enrollment target
- 20
- Study locations
NCT06598943: Recruiting Phase 2 study of Ulcerative Colitis and Ulcerative Colitis Chronic, sponsored by Eli Lilly and Company.
NCT06598943 is a Phase 2 study of Ulcerative Colitis and Ulcerative Colitis Chronic that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 140 participants, below the 2,056-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (93% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06598943, a Phase 2 study of Ulcerative Colitis and Ulcerative Colitis Chronic, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 140 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to determine the safety and efficacy of eltrekibart and mirikizumab in adult participants with moderately to severely active ulcerative colitis (UC).
Primary Outcome
Percentage of Participants Achieving Clinical Remission
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Mirikizumab
- DRUG Eltrekibart
Study Locations (20)
California
- Erick Alayo Medical Corp/Gastro SB Clinic - Chula Vista
- Southern California GI and Liver Centers (SCLC) - Coronado
- Valley View Research - Garden Grove
- Om Research, LLC - Lancaster
- United Medical Doctors - Los Alamitos
- Clinnova Research - Orange
- Prospective Research Innovations - Rancho Cucamonga
- Clinical Trials Management Services, LLC - Thousand Oaks
- Om Research LLC - Victorville
Florida
- Novum Research, LLC - Clermont
- I.V.A.M. Clinical & Investigational Center, LLC - Doral
- Florida Research Institute - Lakewood Rch
- Well Pharma Medical Research Corp. - Miami
- Reserka - Miami
- Digestive Disease Consultants DDCJAX - Orange Park
Arkansas
- Applied Research Center of Arkansas - Little Rock
- Preferred Research Partners - Little Rock
Arizona
- AZ Gastro Care - Chandler - Chandler
Colorado
- Peak Gastroenterology Associates - Colorado Springs
Connecticut
- Medical Research Center of Connecticut, LLC - Hamden
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2024-10-10 |
| Est. Completion | 2028-09 |
| Phase | Phase 2 |
What NCT06598943 shows while recruiting
NCT06598943 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, below the 2,056-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (93% lower).
The record links to 2 conditions, with Ulcerative Colitis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06598943 names 20 study sites across 6 states, led by California, Florida, Arkansas.
Frequently Asked Questions
What is clinical trial NCT06598943 about?
NCT06598943 is a clinical study titled "A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis". The main purpose of this study is to determine the safety and efficacy of eltrekibart and mirikizumab in adult participants with moderately to severely active ulcerative colitis (UC).
What is the current status of trial NCT06598943?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 140 participants. The study started on 2024-10-10. Estimated completion is 2028-09.
What conditions does trial NCT06598943 study?
This clinical trial studies the following conditions: Ulcerative Colitis, Ulcerative Colitis Chronic.
What interventions are being tested in trial NCT06598943?
The interventions under investigation include: Placebo (DRUG), Mirikizumab (DRUG), Eltrekibart (DRUG).
Who is sponsoring clinical trial NCT06598943?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06598943 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ulcerative Colitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06598943's enrollment target sits among peer trials
140 51st of 122 higher than 71 of 122 other Ulcerative Colitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ulcerative Colitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
RECRUITING · Phase 2
-
Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 2
-
Treatment of UC With Novel Therapeutics
RECRUITING · Phase 2
-
A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis
RECRUITING · Phase 2
-
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 2
-
A Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participants With Ulcerative Colitis
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI